Adropin and Irisin as Potential Patentable Biomarkers in Metabolic-Associated Fatty Liver Disease: Current Evidence and Future Directions.
- DOI
- 10.2174/0118722083404498260209095141
- Published
- 2026 May 12
- Container
- Recent patents on biotechnology
- Publisher
- Not recorded
- Open access
- unknown
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.2174/0118722083404498260209095141,
title = {Adropin and Irisin as Potential Patentable Biomarkers in Metabolic-Associated Fatty Liver Disease: Current Evidence and Future Directions.},
author = {Roshni D and Saleem Z and Kamplikar P and Ray SK and Kotnis A and Kanwar JR and Mukherjee S},
year = {2026},
journal = {Recent patents on biotechnology},
doi = {10.2174/0118722083404498260209095141},
url = {https://doi.org/10.2174/0118722083404498260209095141}
}RIS
TY - JOUR TI - Adropin and Irisin as Potential Patentable Biomarkers in Metabolic-Associated Fatty Liver Disease: Current Evidence and Future Directions. AU - Roshni D AU - Saleem Z AU - Kamplikar P AU - Ray SK AU - Kotnis A AU - Kanwar JR AU - Mukherjee S PY - 2026 JO - Recent patents on biotechnology DO - 10.2174/0118722083404498260209095141 UR - https://doi.org/10.2174/0118722083404498260209095141 ER -
APA
D, R., Z, S., P, K., SK, R., A, K., JR, K., & S, M. (2026). Adropin and Irisin as Potential Patentable Biomarkers in Metabolic-Associated Fatty Liver Disease: Current Evidence and Future Directions.. Recent patents on biotechnology. https://doi.org/10.2174/0118722083404498260209095141
Source records
- pubmed · retrieved 2026-09-26T11:30:37.726Z